Friday, July 30, 2021 Daily Archives

Sartorius buys media firm Xell among ‘lively’ M&A environment

by

Xell AG is only Sartorius’s second acquisition this year despite CEO Joachim Kreuzburg saying his firm look at numerous &A activities each week. The €50 million ($60 million) deal sees Sartorius add German firm Xell to its subgroup Sartorius Stedim Biotech, extending its media and feed supplement business for cell cultures. Xell also expands Sartorius’ analytical services for characterizing, screening, and quantifying media components, as well as for optimizing media composition. “With this acquisition, we are expanding our current media…

July 30, 2021

Resilience forks out $110m for Bluebird site in cell therapy partnership

by

Resilience will acquire Bluebird’s North Carolina lentiviral vector manufacturing facility for $110 million, kickstarting an alliance to drive R&D and cell therapy production. Under the terms of the deal, Resilience will acquire Bluebird’s 125,000 square-foot manufacturing plant in Durham, North Carolina, which it only opened two years ago after acquiring the facility in November 2017 and investing $80 million in the site. Bluebird will receive the $110 million upfront and have preferred lentiviral vector (LVV) production access. The firm claims…

July 30, 2021

Bayview’s back: FDA gives Emergent green light to resume vaccine production

by

Emergent took a $54 million hit from remediation efforts and inventory write-downs at its Bayview plant and saw a $108 million reduction in its CDMO backlog. But now the firm is free to restart vaccine production for customer J&J. Emergent BioSolution’s Bayview, Maryland facility had been contracted by both Johnson & Johnson and AstraZeneca to make their respective COVID-19 vaccines, but an ingredient mix up rendered 15 million doses unusable and landed the plant with a Form 483 and a directive…

July 30, 2021